Clinical Trials

    Showing 1 - 10 of 36 Other

    Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

    Status: Enrolling

    Investigator: Warren Ellsworth

    Study Coordinator: Valentina Villarroel

    Phone: 346.238.4384

    This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparative a... Read more >

    A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

    Status: Open Not Enrolling

    Investigator: Bincy Abraham

    Study Coordinator:

    Phone:

    This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.... Read more >

    A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

    Status: Enrolling

    Investigator: Aldona Spiegel

    Study Coordinator: Valentina Villarroel

    Phone: 346.238.4384

    This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparative a... Read more >

    A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

    Status: Open Not Enrolling

    Investigator: David Victor

    Study Coordinator: Beatriz Efron

    Phone: 713.363.8890

    Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC).... Read more >

    A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

    Status: Open Not Enrolling

    Investigator: Michael Klebuc

    Study Coordinator: Darrel Cleere

    Phone: 713.441.6232

    This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room. The main purposes of this study are to 1) see how safe NTX-001 is when used in nerve rep... Read more >

    A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias treated Robotically with OviTex® Reinforced Tissue Matrix

    Status: Open Not Enrolling

    Investigator: Nabil Tariq

    Study Coordinator: Nicole Hinton

    Phone: 281.755.0796

    This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.... Read more >

    A randomized, double-blind, placebo controlled, dosefinding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis

    Status: Enrolling

    Investigator: Bincy Abraham

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further c... Read more >

    A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2/fibrosis 3 stage of liver fibrosis

    Status: Enrolling

    Investigator: David Victor

    Study Coordinator: Beatriz Efron

    Phone: 713.363.8890

    This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adults w... Read more >

    A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

    Status: Enrolling

    Investigator: Sandeep Sahay

    Study Coordinator: Rosa Barrosa da Costa

    Phone: 713.441.5660

    Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.... Read more >

    A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

    Status: Enrolling

    Investigator: Lisa Kopas

    Study Coordinator: Brooke Shope

    Phone: 713.441.3248

    This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this st... Read more >

    ABTECT - Maintenance

    Status: Open Not Enrolling

    Investigator: Bincy Abraham

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate re... Read more >

    ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

    Status: Open Not Enrolling

    Investigator: Bincy Abraham

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate res... Read more >

    An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension (ASCENT Study) LTI-401

    Status: Enrolling

    Investigator: Mohi Syed

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability ofLIQ861 in subjects who have WHO Group 1 & 3 PH. Cohort A will include approximately 60 subjects who have WHO Group 3 Pulmonary Hypertension associated... Read more >

    An Open-label, Phase II, Pre-operative Study of Atezolizumab plus Bevacizumab for Resectable Hepatocellular Carcinoma

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Beatriz Efron

    Phone: 713.363.8890

    This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for dise... Read more >

    Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier (NIGHTINGALE)

    Status: Enrolling

    Investigator: Lisa Kopas

    Study Coordinator: Brooke Shope

    Phone: 713.441.3248

    The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: Does the use of the Percepta... Read more >

    Corrona Inflammatory Bowel Disease (IBD) Registry

    Status: Enrolling

    Investigator: Bincy Abraham

    Study Coordinator:

    Phone:

    This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Secondary o... Read more >

    DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

    Status: Open Not Enrolling

    Investigator: Meagan Chavarria

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    The purpose of this study is to observe and capture demographic characteristics, treatment patterns, and clinical outcomes of interest for patients with PH-ILD to further clinical understanding of the epidemiological landscape and outcomes of the dis... Read more >

    Effi cacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (ENHANCE-CD)

    Status: Enrolling

    Investigator: Bincy Abraham

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy... Read more >

    Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied thr... Read more >

    N/A

    Status: Enrolling

    Investigator: Sunil Dacha

    Study Coordinator:

    Phone:

    The goal of this research is to learn about pyloric sphincter characteristics (measure sphincter pressure, area, and elasticity) in both patients with gastroparesis and without gastroparesis using the endoscopic functional lumen imaging probe (EndoFL... Read more >

    NMDA Receptor in Psychosis: Specific Auto-Antibodies

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator:

    Phone:

    Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N-acety... Read more >

    Ocrelizumab for Psychosis by Autoimmunity (OPA)

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack ... Read more >

    Pulmonary Hypertension Association Registry (PHAR)

    Status: Open Not Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Royanne Holy

    Phone: 713.363.7536

    The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participa... Read more >

    Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

    Status: Enrolling

    Investigator: Sandeep Sahay

    Study Coordinator: Herpreet Sandhu

    Phone: 713.441.5660

    Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). In this study, subjects will undergo a broad range of... Read more >

    Randomized Controlled Trial Comparing NEUROMARK System to Sham Control in Patients With Chronic Rhinitis

    Status: Enrolling

    Investigator: Masayoshi Takashima

    Study Coordinator: Tariq Syed

    Phone: 346.238.6466

    The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial.... Read more >

    Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

    Status: Enrolling

    Investigator: Masayoshi Takashima

    Study Coordinator: Tariq Syed

    Phone: 346.238.6466

    The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064. The study will take approximately 32 weeks which will inclu... Read more >

    REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

    Status: Enrolling

    Investigator: Christopher Fan

    Study Coordinator:

    Phone:

    This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBY... Read more >

    Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (Target CD)

    Status: Enrolling

    Investigator: Malcolm Irani

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weig... Read more >

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Ana Lucia Varon Ocampo

    Phone: 713.363.8024

    Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific background t... Read more >

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Ana Lucia Varon Ocampo

    Phone: 713.363.8024

    Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. Subjec... Read more >

    Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough (ASPIRE)

    Status: Enrolling

    Investigator: Lisa Kopas

    Study Coordinator: Brooke Shope

    Phone: 713.441.3248

    This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough. Approximatel... Read more >

    Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/?REGN3500/?Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

    Status: Enrolling

    Investigator: Lisa Kopas

    Study Coordinator: Brooke Shope

    Phone: 713.441.3248

    Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD... Read more >

    To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

    Status: Enrolling

    Investigator: William Ondo

    Study Coordinator: Daniel Arnaud Dominguez

    Phone: 346.356.3635

    This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150... Read more >

    VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

    Status: Enrolling

    Investigator: Bincy Abraham

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH u... Read more >

    X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

    Status: Open Not Enrolling

    Investigator: Laila Tabatabai

    Study Coordinator: Melissa Whipple

    Phone: 713.441.3247

    The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of burosumab... Read more >

    Zephyr Valve Registry (ZEVR) (ZEVR)

    Status: Enrolling

    Investigator: Lisa Kopas

    Study Coordinator: Brooke Shope

    Phone: 713.441.3248

    The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting. The Zephyr Valve Registry (ZEVR) is a multi-center, single-arm, prospective Registry. The ob... Read more >